{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:02:27Z","timestamp":1792839747677,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s10620-023-07916-2","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T13:05:29Z","timestamp":1680786329000},"page":"3193-3198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Low Rate of Hepatitis B Reactivation Among Patients with Chronic Hepatitis C During Direct Acting Antiviral Therapy"],"prefix":"10.1007","volume":"68","author":[{"given":"Nehna Abdul","family":"Majeed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Samer","family":"Alawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kin Seng","family":"Liem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Takyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey","family":"Alter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L. A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2837-0188","authenticated-orcid":false,"given":"Marc G.","family":"Ghany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"7916_CR1","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","volume":"152","author":"R Loomba","year":"2017","unstructured":"Loomba R, Liang TJ. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology 2017;152:1297\u20131309.","journal-title":"Gastroenterology"},{"key":"7916_CR2","unstructured":"https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-about-risk-hepatitis-b-reactivating-some-patients-treated. Last accessed November 1st, FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct -acting antivirals for hepatitis C. 2016. 2016."},{"key":"7916_CR3","doi-asserted-by":"publisher","first-page":"760","DOI":"10.7326\/L17-0477","volume":"167","author":"SJ Bersoff-Matcha","year":"2017","unstructured":"Bersoff-Matcha SJ et al. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus. Ann Intern Med 2017;167:760.","journal-title":"Ann Intern Med"},{"key":"7916_CR4","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1053\/j.gastro.2017.11.011","volume":"154","author":"CJ Liu","year":"2018","unstructured":"Liu CJ et al. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. Gastroenterology 2018;154:989\u2013997.","journal-title":"Gastroenterology"},{"key":"7916_CR5","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S2468-1253(18)30002-5","volume":"3","author":"MM Mucke","year":"2018","unstructured":"Mucke MM et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2018;3:172\u2013180.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"7916_CR6","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.3748\/wjg.v24.i28.3181","volume":"24","author":"XW Jiang","year":"2018","unstructured":"Jiang XW et al. Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis. World J Gastroenterol 2018;24:3181\u20133191.","journal-title":"World J Gastroenterol"},{"key":"7916_CR7","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1111\/liv.13874","volume":"38","author":"M El Kassas","year":"2018","unstructured":"El Kassas M et al. Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: A cohort study from Egypt and meta-analysis of published data. Liver Int 2018;38:2159\u20132169.","journal-title":"Liver Int"},{"key":"7916_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/hep.29109","volume":"66","author":"G Chen","year":"2017","unstructured":"Chen G et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis. Hepatology 2017;66:13\u201326.","journal-title":"Hepatology"},{"key":"7916_CR9","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41598-020-57603-9","volume":"10","author":"K Murai","year":"2020","unstructured":"Murai K et al. Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway. Sci Rep 2020;10:941.","journal-title":"Sci Rep"},{"key":"7916_CR10","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1172\/JCI135616","volume":"130","author":"X Cheng","year":"2020","unstructured":"Cheng X et al. Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection. J Clin Invest 2020;130:3205\u20133220.","journal-title":"J Clin Invest"},{"key":"7916_CR11","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1016\/j.cgh.2021.11.032","volume":"20","author":"PN Cheng","year":"2022","unstructured":"Cheng PN et al. Entecavir Prevents HBV Reactivation During Direct Acting Antivirals for HCV\/HBV Dual Infection: A Randomized Trial. Clin Gastroenterol Hepatol 2022;20:2800\u20132808.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7916_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/hep.29135","volume":"66","author":"PS Belperio","year":"2017","unstructured":"Belperio PS et al. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. Hepatology 2017;66:27\u201336.","journal-title":"Hepatology"},{"key":"7916_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.cgh.2016.06.023","volume":"15","author":"C Wang","year":"2017","unstructured":"Wang C et al. Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents. Clin Gastroenterol Hepatol 2017;15:132\u2013136.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7916_CR14","doi-asserted-by":"publisher","first-page":"ofy340","DOI":"10.1093\/ofid\/ofy340","volume":"6","author":"MM Mucke","year":"2019","unstructured":"Mucke MM et al. Absence of HBV Reactivation in Patients With Resolved HBV Infection Following DAA Therapy for Hepatitis C: A 1-Year Follow-up Study. Open Forum Infect Dis 2019;6:ofy340.","journal-title":"Open Forum Infect Dis"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-07916-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-023-07916-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-07916-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T16:16:09Z","timestamp":1687796169000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-023-07916-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["7916"],"URL":"https:\/\/doi.org\/10.1007\/s10620-023-07916-2","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,6]]},"assertion":[{"value":"8 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Marc G. Ghany accepts full responsibility for the conduct of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}}]}}